Drug Trial Radar · NCT02972840
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
635
Actual
Start
Apr 5, 2017
Primary completion
Feb 15, 2027
Study completion Feb 15, 2027
Sponsor
- Lead sponsor
- Acerta Pharma BVAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- AstraZeneca
- First posted
- Nov 25, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.
Conditions
- Lymphoma, Mantle Cell
Interventions
AcalabrutinibDrug
Administered orally (PO)
BendamustineDrug
Administered intravenously (IV)
RituximabDrug
Administered intravenously (IV)
PlaceboDrug
Placebo comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival per the Lugano Classification for NHL in Arm 1 compared to Arm 2Time frame: Up to 6 years
Locations
228 sites in 27 countries. Site status is shown where the registry gives one.
Research Site
Tucson, Arizona
Research Site
Downey, California
Research Site
Santa Monica, California
Research Site
New Haven, Connecticut
Research Site
Washington D.C., District of Columbia
Research Site
Tallahassee, Florida
Research Site
West Palm Beach, Florida
Research Site
Marietta, Georgia
Research Site
Westwood, Kansas
Research Site
Louisville, Kentucky
Research Site
Ann Arbor, Michigan
Research Site
Rochester, Minnesota
Research Site
Kansas City, Missouri
Research Site
St Louis, Missouri
Research Site
Hackensack, New Jersey
Research Site
Morristown, New Jersey
Research Site
Hawthorne, New York
Research Site
Lake Success, New York
Research Site
Portland, Oregon
Research Site
Charleston, South Carolina
Research Site
Greenville, South Carolina
Research Site
Chattanooga, Tennessee
Research Site
Nashville, Tennessee
Research Site
Houston, Texas
Research Site
San Antonio, Texas
Research Site
Tyler, Texas
Research Site
Charlottesville, Virginia
Research Site
Fort Belvoir, Virginia
Research Site
Seattle, Washington
Research Site
Seattle, Washington
Research Site
Seattle, Washington
Research Site
Morgantown, West Virginia
Research Site
Buenos Aires, Argentina
Research Site
Buenos Aires, Argentina
Research Site
Buenos Aires, Argentina
Research Site
Buenos Aires, Argentina
Research Site
Caba, Argentina
Research Site
Córdoba, Argentina
Research Site
Bedford Park, Australia
Research Site
Concord, Australia
Showing 40 of 228 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.